GMAB News and Press, Genmab A/S From 05/25/23

Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma across multiple lines of therapy and histologies where high unmet needs exist Gen...

2023-05-19 12:59:30 ET AbbVie ( NYSE: ABBV ) and Genmab A/S ( GMAB ) announced Friday that the FDA approved Epkinly, a bispecific antibody therapy, as a late-line option for adults with white blood cell cancer large B-cell lymphoma (DLBCL). Specifically, the FDA’s l...

Company Announcement Results from phase 2 clinical trial demonstrated EPKINLY ™ (epcoritamab- bysp ) delivered 61 percent overall response rate , 38 percent complete response, and 15. 6 -month median duration of response in ...

2023-05-11 08:25:47 ET Polar Power ( POLA ) +66% now taking pre-orders for new line of mobile EV chargers, stock jumps 52%. MMTec ( MTC ) +24% . Home Point Capital ( HMPT ) +18% to acquire Home Point Capital for $324M in cash. AppLovin Corporation ( A...

2023-05-10 18:07:08 ET Genmab A/S (GMAB) Q1 2023 Earnings Conference Call May 10, 2023, 12:00 ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Conference Call Participants Michael Schmidt - Guggenh...

2023-05-10 13:11:48 ET Genmab A/S press release ( GMAB ): Q1 GAAP EPS of DKK3.43 beats by DKK3.27 . Revenue of DKK2.26B (+21.5% Y/Y). For further details see: Genmab A/S GAAP EPS of DKK3.43 beats by DKK3.27, revenue of DKK2.26B

May 10 , 202 3 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023 Highlights Genmab revenue increased 3 5 % compared to the first quarter of 2022, to DKK 2,85 4 million “In the f...

2023-05-04 04:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund gained 3.75% (Institutional Shares) during the first q...

2023-04-29 16:00:00 ET With the first trading day in May coming on Monday, many pharmaceutical companies will be hoping their returns fare better than they did in April. The iShares U.S. Pharmaceuticals ETF ( IHE ) returned a paltry 1.6% in April. The ETF's top two holdings are ...

2023-04-25 10:00:20 ET Summary Arbitration dismissal: Genmab's recent dismissal of its second arbitration case against Janssen regarding Darzalex Faspro royalties suggests that these royalties will likely cease after 2030. PDUFA date and pipeline focus: The market's attention shou...